Tear Film Stabilization and Symptom Improvement in Dry Eye Disease: The Role of Hyaluronic Acid and Trehalose Eyedrops Versus Carmellose Sodium

Overview

Journal J Clin Med

Specialty General Medicine

Date 2023 Oct 28

PMID 37892784

Authors

Jose-Maria Sanchez-Gonzalez

Carmen Silva-Viguera

Maria Carmen Sanchez-Gonzalez

Raul Capote-Puente

Concepcion De-Hita-Cantalejo

Antonio Ballesteros-Sanchez

Lydia Ballesteros-Duran

Marta-C Garcia-Romera

Estanislao Gutierrez-Sanchez

Affiliations

Soon will be listed here.

Abstract

This study evaluated the effectiveness of hyaluronic acid and trehalose (HA/trehalose) eyedrops in managing dry eye disease (DED) symptoms by measuring tear stability and administering a DED questionnaire. Sixty patients were treated with either HA/trehalose eyedrops (Tear A) or carmellose sodium eyedrops (Tear B) as controls. The tear breakup time (TBUT) and non-invasive breakup time (NIBUT) were monitored, and patients completed the standard patient evaluation of eye dryness (SPEED) questionnaire. After two months of twice-daily applications, patients treated with the HA/trehalose eyedrops demonstrated significant improvements in the NIBUT (12.98 ± 3.22 s) and TBUT (12.95 ± 2.98 s), indicating increased tear stability. Moreover, they reported lower dry eye sensation (6.70 ± 4.94 SPEED score points), suggesting a reduction in DED symptoms. These findings underscore the efficacy of HA/trehalose eyedrops in improving both the objective and subjective signs of DED, with twice-daily application enhancing ocular surface conditions and reducing patient-reported symptoms.

Citing Articles

A Preservative-Free Combination of Sodium Hyaluronate and Trehalose Improves Dry Eye Signs and Symptoms and Increases Patient Satisfaction in Real-Life Settings: The TEARS Study.

Mateo-Orobia A, Farrant S, Del-Prado-Sanz E, Blasco-Martinez A, Idoipe-Corta M, Lafuente-Ojeda N Ophthalmol Ther. 2024; 13(12):3123-3134.

PMID: 39432158 PMC: 11564544. DOI: 10.1007/s40123-024-01044-4.

Topical Solution for Retinal Delivery: Bevacizumab and Ranibizumab Eye Drops in Anti-Aggregation Formula (AAF) in Rabbits.

Giannos S, Kraft E, Luisi J, Schmitz-Brown M, Reffatto V, Merkley K Pharm Res. 2024; 41(6):1247-1256.

PMID: 38839719 PMC: 11196329. DOI: 10.1007/s11095-024-03721-2.

References

Ngo W, Situ P, Keir N, Korb D, Blackie C, Simpson T . Psychometric properties and validation of the Standard Patient Evaluation of Eye Dryness questionnaire. Cornea. 2013; 32(9):1204-10. DOI: 10.1097/ICO.0b013e318294b0c0. View

Schmidl D, Schmetterer L, Witkowska K, Unterhuber A, Aranha Dos Santos V, Kaya S . Tear film thickness after treatment with artificial tears in patients with moderate dry eye disease. Cornea. 2015; 34(4):421-6. DOI: 10.1097/ICO.0000000000000358. View

Astolfi G, Lorenzini L, Gobbo F, Sarli G, Versura P . Comparison of Trehalose/Hyaluronic Acid (HA) vs. 0.001% Hydrocortisone/HA Eyedrops on Signs and Inflammatory Markers in a Desiccating Model of Dry Eye Disease (DED). J Clin Med. 2022; 11(6). PMC: 8948919. DOI: 10.3390/jcm11061518. View

Lyu Y, Zeng X, Li F, Zhao S . The effect of the duration of diabetes on dry eye and corneal nerves. Cont Lens Anterior Eye. 2019; 42(4):380-385. DOI: 10.1016/j.clae.2019.02.011. View

Pinto-Bonilla J, Del Olmo-Jimeno A, Llovet-Osuna F, Hernandez-Galilea E . A randomized crossover study comparing trehalose/hyaluronate eyedrops and standard treatment: patient satisfaction in the treatment of dry eye syndrome. Ther Clin Risk Manag. 2015; 11:595-603. PMC: 4403513. DOI: 10.2147/TCRM.S77091. View

Mencucci R, Favuzza E, Decandia G, Cennamo M, Giansanti F . Hyaluronic Acid/Trehalose Ophthalmic Solution in Reducing Post-Cataract Surgery Dry Eye Signs and Symptoms: A Prospective, Interventional, Randomized, Open-Label Study. J Clin Med. 2021; 10(20). PMC: 8538593. DOI: 10.3390/jcm10204699. View

Mateo Orobia A, Saa J, Ollero Lorenzo A, Herreras J . Combination of hyaluronic acid, carmellose, and osmoprotectants for the treatment of dry eye disease. Clin Ophthalmol. 2018; 12:453-461. PMC: 5846763. DOI: 10.2147/OPTH.S157853. View

Cagini C, Di Lascio G, Torroni G, Mariniello M, Meschini G, Lupidi M . Dry eye and inflammation of the ocular surface after cataract surgery: effectiveness of a tear film substitute based on trehalose/hyaluronic acid vs hyaluronic acid to resolve signs and symptoms. J Cataract Refract Surg. 2021; 47(11):1430-1435. DOI: 10.1097/j.jcrs.0000000000000652. View

Luyckx J, Baudouin C . Trehalose: an intriguing disaccharide with potential for medical application in ophthalmology. Clin Ophthalmol. 2011; 5:577-81. PMC: 3102588. DOI: 10.2147/OPTH.S18827. View

10.

Wolffsohn J, Arita R, Chalmers R, Djalilian A, Dogru M, Dumbleton K . TFOS DEWS II Diagnostic Methodology report. Ocul Surf. 2017; 15(3):539-574. DOI: 10.1016/j.jtos.2017.05.001. View

11.

Novack G, Asbell P, Barabino S, Bergamini M, Ciolino J, Foulks G . TFOS DEWS II Clinical Trial Design Report. Ocul Surf. 2017; 15(3):629-649. PMC: 8557254. DOI: 10.1016/j.jtos.2017.05.009. View

12.

Cagini C, Torroni G, Mariniello M, Di Lascio G, Martone G, Balestrazzi A . Trehalose/sodium hyaluronate eye drops in post-cataract ocular surface disorders. Int Ophthalmol. 2021; 41(9):3065-3071. PMC: 8364531. DOI: 10.1007/s10792-021-01869-z. View

13.

Craig J, Nichols K, Akpek E, Caffery B, Dua H, Joo C . TFOS DEWS II Definition and Classification Report. Ocul Surf. 2017; 15(3):276-283. DOI: 10.1016/j.jtos.2017.05.008. View

14.

Thulasi P, Djalilian A . Update in Current Diagnostics and Therapeutics of Dry Eye Disease. Ophthalmology. 2017; 124(11S):S27-S33. PMC: 6660902. DOI: 10.1016/j.ophtha.2017.07.022. View

15.

Bron A, de Paiva C, Chauhan S, Bonini S, Gabison E, Jain S . TFOS DEWS II pathophysiology report. Ocul Surf. 2017; 15(3):438-510. DOI: 10.1016/j.jtos.2017.05.011. View

16.

Cejka C, Kubinova S, cejkova J . Trehalose in ophthalmology. Histol Histopathol. 2019; 34(6):611-618. DOI: 10.14670/HH-18-082. View

17.

Mateo Orobia A, Casas Pascual P, Cristobal Bescos J, Perez Garcia D, Peiro Embid C, Del Buey Sayas M . Effects of 3% trehalose as an adjuvant treatment after LASIK. Clin Ophthalmol. 2017; 11:347-353. PMC: 5317334. DOI: 10.2147/OPTH.S125203. View

18.

Downie L, Hom M, Berdy G, El-Harazi S, Verachtert A, Tan J . An artificial tear containing flaxseed oil for treating dry eye disease: A randomized controlled trial. Ocul Surf. 2019; 18(1):148-157. DOI: 10.1016/j.jtos.2019.11.004. View

19.

Caretti L, La Gloria Valerio A, Piermarocchi R, Badin G, Verzola G, Masara F . Efficacy of carbomer sodium hyaluronate trehalose vs hyaluronic acid to improve tear film instability and ocular surface discomfort after cataract surgery. Clin Ophthalmol. 2019; 13:1157-1163. PMC: 6629019. DOI: 10.2147/OPTH.S208256. View

20.

Fondi K, Wozniak P, Schmidl D, Bata A, Witkowska K, Popa-Cherecheanu A . Effect of Hyaluronic Acid/Trehalose in Two Different Formulations on Signs and Symptoms in Patients with Moderate to Severe Dry Eye Disease. J Ophthalmol. 2018; 2018:4691417. PMC: 6093073. DOI: 10.1155/2018/4691417. View